Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

This study is testing a new cellular immunotherapy — engineered natural killer (NK) cells derived from cord blood and modified to target a protein called TROP2 found on certain cancer cells — delivered directly into the belly (intraperitoneally) for people with platinum-resistant ovarian cancer, a rare type of uterine-like cancer called mesonephric-like adenocarcinoma, or pancreatic cancer that has spread to the abdominal cavity. **You may be eligible if:** - You are 18 or older and have a confirmed diagnosis of one of the qualifying cancers: platinum-resistant ovarian cancer, mesonephric-like adenocarcinoma, or pancreatic cancer - Your tumor tests positive for TROP2 protein expression by staining - You have measurable disease, including disease in or near the abdominal (peritoneal) cavity - You are in good physical condition (ECOG 0–1) with adequate organ function - You are willing to have an intraperitoneal port placed and to provide blood and peritoneal fluid samples - It has been at least 3 weeks since your last chemotherapy **You may NOT be eligible if:** - Your tumor does not express TROP2 - You have no disease within the abdominal or peritoneal cavity - Your organ function is insufficient to tolerate treatment - You are unable to undergo port placement or provide samples Talk to your doctor to see if this trial is right for you.